In liposomal delivery system, performance depends on whether nutrients can be protected, absorbed and utilized as intended. That principle defines EffePharm’s LipoAvail^® platform, a clinically supported liposomal delivery system designed to improve the oral bioavailability of active ingredients in ways that can be measured and validated. Rather than treating liposomes as a formulation feature, EffePharm approaches them as a delivery technology built around structural precision, scientific validation and scalable manufacturing. Such a focus has helped position the company as a specialist in liposomal technology for nutraceutical brands seeking proven performance. “Most products stop at formulation. We start there. Our role is to ensure that every ingredient is delivered in a way the body can recognize, absorb and retain. Without that, even the best ingredients lose their value,” says Alex Shen, CEO. From Liposome Concept to Proven Delivery System Liposomal delivery system has long been associated with improved bioavailability, but not all liposomes perform equally. Variability in particle size, Morphology, encapsulation efficiency and formulation stability often limits performance. EffePharm developed LipoAvail^® technology to address those challenges through controlled engineering and data-backed validation. Using phospholipid bilayers designed to resemble human cell membranes, LipoAvail^® liposomes protect active compounds while supporting absorption through multiple biological pathways, including membrane fusion and endocytic uptake. With particle sizes typically below 100 nanometers and uniform spherical morphology verified through transmission electron microscopy, the LipoAvail^® liposomal technology is designed to support both protection and efficient transport. .

What factors influence tissue healing and adhesion prevention during the postoperative recovery window today? Long-term surgical recovery is often defined less by the procedure itself than by what happens during the critical healing window following surgery, when tissues heal and postoperative adhesions can form. It is within this window that BioRegen operates, developing proprietary hyaluronic acid-based biomaterials designed to prevent adhesions and promote tissue repair. BioRegen’s hallmark is its internationally patented Self-Crosslinking of Hyaluronic Acid technology, designed to address a persistent clinical challenge. Conventional anti-adhesion barriers often degrade too quickly or exhibit high fluidity, migrating from the application site before the critical healing phase is complete. The solution creates a stable three-dimensional network without synthetic additives, allowing its semi-solid gels to remain in place for seven to fourteen days, the period most associated with adhesion formation. The gel forms a physical barrier that separates adjacent tissues while maintaining structural integrity throughout this period and then degrades without residue. Combined with approximately 22-fold enhanced viscosity, the technology represents a targeted biomaterial solution combining technological differentiation with proven clinical efficacy. “Our materials are based on hyaluronic acid, a natural component of the extracellular matrix. They actively promote wound healing and tissue regeneration at the surgical site,” says Andong Chen, Overseas Business Manager at BioRegen. The company’s impact lies in how its biomaterial science translates into clinical value. In specialties such as gynecology and ENT surgery, where adhesions can contribute to infertility, chronic pain or repeat interventions, prevention carries outsized importance. Rather than treating biomaterials as passive barriers, BioRegen positions them as healing platforms that both prevent unwanted tissue attachment and support tissue repair..

Animal health is at a crossroads, as antibiotics face growing scrutiny and vaccine effectiveness continues to fall short. ADBIOTECH is stepping into that gap with purpose. As a next-generation player in animal immunotherapy, it has developed two breakthrough antibody platforms—IgY and nanobodies—to shift the industry from reactive treatment to proactive prevention. Its IgY technology is already being used to reinforce immunity and enhance vaccine performance in livestock and aquaculture. Meanwhile, its early exploration into nanobodies (single-domain antibodies known for their stability and specificity) points to ADBIOTECH’s frontrunner vision of redefining animal disease control through targeted, immune-based solutions that reduce reliance on antibiotics. In doing so, ADBIOTECH is setting a new standard for addressing animal health challenges globally. The best part is that the antibodies are produced through natural biological processes. IgY is derived from immunizing poultry, collecting their eggs and extracting antibodies from the yolks. It’s administered orally, allowing it to act directly in the gastrointestinal tract, where many infections begin due to pathogen entry through food. The antibodies are especially valuable for offering a noninvasive, targeted response. Nanobodies, on the other hand, are derived from camelids like llamas and alpacas, which naturally produce a unique form of antibody. These are about one-tenth the size of conventional antibodies, penetrating tissues more effectively and delivering precise, injectable treatments. The efficacy lasts 30 days with a single injection, a far more long-acting protection with minimal intervention. “Managing every step in-house, from pure antigen selection to large-scale manufacturing, within our Korea Good Manufacturing Practice-certified facility, we ensure uncompromised oversight across the full development lifecycle, translating scientific rigor into reliable, market-ready solutions,” says Hong Gul Cheong, CEO. ADBIOTECH is continually advancing its nanobody technology to improve efficacy and expand its applications. One such breakthrough is the development of bivalent nanobodies, which link two nanobodies into a single construct. This increases binding strength or enables simultaneous targeting of multiple pathogens. Another innovation is Fc domain binding, where nanobodies are fused with the Fc region of an antibody to extend half-life and enhance immune system engagement. These advances are making a difference in the field, making it possible to prevent diseases such as calf diarrhea, porcine reproductive and respiratory syndrome (PRRS), porcine epidemic diarrhea (PED) and other high-impact conditions affecting livestock health and farm productivity..